Clinical Trial

Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD

Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this registry study is to evaluate the therapeutic efficacy and safety profiles of distinct monoclonal antibody-based therapies for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorders within the Chinese population under real-world clinical conditions. Secondary objectives include quantitative assessment of longitudinal neuroimaging biomarker variations and immunological profile alterations in longitudinal biological specimens pre- and post-therapeutic intervention.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-13; most recent amendment 2025-09-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT06885957
Lead Sponsor Tongji Hospital
Conditions NMO Spectrum Disorder
Enrollment 200 participants
Start Date 2025-07-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-08